BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35739428)

  • 21. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
    Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
    Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
    Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
    Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
    Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
    Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
    J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
    Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
    Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Récher C; Yoon SS; Hosono N; Onozawa M; Chiba S; Kim HJ; Hasabou N; Lu Q; Tiu R; Levis MJ
    Blood; 2022 Jun; 139(23):3366-3375. PubMed ID: 35081255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
    Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
    J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
    Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
    Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
    Miyajima T; Harada S; Ogasawara R; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Chi S; Minami Y; Kondo T
    Rinsho Ketsueki; 2022; 63(1):51-54. PubMed ID: 35135952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Ngo D; Tinajero J; Li S; Palmer J; Pourhassan H; Aribi A; Nakamura R; Stein A; Marcucci G; Salhotra A; Sandhu K; Pullarkat V; Ball B; Koller P
    Leuk Lymphoma; 2024 Mar; 65(3):372-377. PubMed ID: 38164785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel approach for relapsed/refractory FLT3
    Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
    Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
    Pratz KW; Cherry M; Altman JK; Cooper BW; Podoltsev NA; Cruz JC; Lin TL; Schiller GJ; Jurcic JG; Asch A; Wu R; Hill JE; Gill SC; James AJ; Rich ES; Hasabou N; Perl AE; Levis MJ
    J Clin Oncol; 2023 Sep; 41(26):4236-4246. PubMed ID: 37379495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.
    Buelow DR; Bhatnagar B; Orwick SJ; Jeon JY; Eisenmann ED; Stromatt JC; Pabla NS; Blachly JS; Baker SD; Blaser BW
    Blood Adv; 2022 Sep; 6(17):5049-5060. PubMed ID: 35797240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
    Perrone S; Ortu La Barbera E; Viola F; Cipollone E; Scerpa MC; Siniscalchi R; Ottone T; Voso MT; Cimino G
    Chemotherapy; 2021; 66(4):134-138. PubMed ID: 34515081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of Relapsed or Refractory
    Bertoli S; Dumas PY; Bérard E; Largeaud L; Bidet A; Delabesse E; Tavitian S; Gadaud N; Leguay T; Leroy H; Rieu JB; Vial JP; Vergez F; Lechevalier N; Luquet I; Klein E; Sarry A; Grande AC; Récher C; Pigneux A
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gilteritinib: First Global Approval.
    Dhillon S
    Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.